Elise F. Nassif Haddad, M.D., M.S, Ph.D.
Department of Sarcoma Medical Oncology, Division of Cancer Medicine
About Dr. Elise F Nassif
I am a physician-scientist in the Department of Sarcoma Medical Oncology. I received my medical degree in 2014 and my medical oncology specialty in 2020 from Paris University (France). During my residency and fellowship in France, I trained at Gustave Roussy Cancer Center and completed a master of science in Immunology in 2019. After completion of my clinical training, I pursued a research post-doctoral fellowship at MD Anderson during two years, focusing on characterizing the immune microenvironment of sarcomas and identifying new immune therapeutic targets to improve sarcoma care.
I have a particular interest in the care of patients with leiomyosarcomas and undifferentiated pleomorphic sarcomas. My main research focus are leiomyosarcomas, undifferentiated pleomorphic sarcomas, i
mmunotherapy,
and drug development in sarcomas.
Read More
Present Title & Affiliation
Primary Appointment
Assistant Professor (Joint appointment), Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Assistant Professor, Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Assistant Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Assistant Professor, Department of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Clinical Interests
My main areas of focus and expertise are sarcomas, with a particular emphasis on leiomyosarcomas and undifferentiated pleomorphic sarcomas, translational immuno-oncology, and drug development in immunotherapy.
Education & Training
Degree-Granting Education
| 2023 | Université Claude Bernard Lyon 1, Lyon, FR, Oncology, Ph.D |
| 2019 | Université Paris Descartes, Paris, FR, Immunology, M.S |
| 2014 | Université Paris Descartes, Paris, FR, Medicine, MD |
Postgraduate Training
| 2021-2022 | Research Fellowship, Translational immuno-oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2014-2020 | Clinical Fellowship, Medical Oncology, Université Paris Descartes, Paris |
| 2014-2020 | Clinical Residency, Université Paris Descartes, Paris |
Experience & Service
Other Appointments/Responsibilities
Fellowship Coordinator for the Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2023 - Present
Institutional Committee Activities
Member, Fellowship Steering Committee, 2023 - 2023
Honors & Awards
| 2024 | Rising Star Award, The University of Texas MD Anderson Cancer Center |
| 2024 | First Place Award For Clinical Research from Sparkathon, SITC |
| 2023 | Young Investigator Travel Award, SARC, NCI SASS |
| 2023 | Methods in Clinical Cancer research, ASCO/AACR |
| 2022 | GlaxoSmithKline Endowed Merit Award, ASCO / Conquer Cancer |
| 2022 | Clinical Trial Workshop SCION, SITC |
| 2022 | Daniel Benedict Gazan Award in Sarcoma Research, The University of Texas MD Anderson Cancer Center |
| 2022 | Women in Immunotherapy Network, SITC |
| 2021 | Travel Award, European Society for Medical Oncology |
| 2020 | Young Investigator Award, American Radium Society |
| 2019 | Immuno-Oncology preceptorship, ESMO |
| 2019 | ESMO Academy, ESMO |
| 2019 | ESMO Exam, ESMO |
Selected Publications
Peer-Reviewed Articles
- Zoghbi M, Patel BA, Roulleaux Dugage M, Mezquita L, Bahleda R, Dufresne A, Brahmi M, Ray-Coquard I, Pautier P, Blay JY, Le Cesne A, Massard C, Besse B, Auclin E, Nassif Haddad EF. Association of Lung Immune Prognostic Index (LIPI) with Disease Control Rate and Progression-Free Survival in Patients with Soft-Tissue Sarcoma Treated with Immunotherapy in Early-Phase Trials. Cancers (Basel) 16(23), 2024. e-Pub 2024. PMID: 39682239.
- Saab R, Fellman BM, Legarreta AF, Meyer LA, Fleming ND, Ratan R, Nassif Haddad EF, Frumovitz M, Soliman PT. Comparative analysis of hormonal therapy in low-grade endometrial stromal sarcoma: A retrospective study. Gynecol Oncol 191:143-149, 2024. e-Pub 2024. PMID: 39396406.
- Martiniova L, Kamel S, Kairemo K, Benjamin R, Somaiah N, Ravizzini G, Nassif Haddad EF. Predictive Value of Quantitative Parameters of (18)F-FDG PET/CT in Patients with Liposarcoma. Diagnostics (Basel) 14(18), 2024. e-Pub 2024. PMID: 39335700.
- Del Calvo H, Wu Y, Lin HY, Nassif EF, Zarzour MA, Guadagnolo BA, Hunt KK, Bedrosian I, Lillemoe HA. Margin Width and Local Recurrence in Patients with Phyllodes Tumors of the Breast. Ann Surg Oncol 31(12):8048-8056, 2024. e-Pub 2024. PMID: 39085546.
- Traweek RS, Lyu HG, Witt RG, Snyder RA, Nassif EF, Krijgh DD, Smith JM, Tilney GS, Feng C, Chiang YJ, Torres KE, Roubaud MJ, Scally CP, Hunt KK, Keung EZ, Mericli AF, Roland CL. High Community-Level Social Vulnerability is Associated with Worse Recurrence-Free Survival (RFS) After Resection of Extremity and Truncal Soft Tissue Sarcoma. Ann Surg Oncol 31(6):4138-4147, 2024. e-Pub 2024. PMID: 38396039.
- Traweek, R, Lyu, H, Witt, RG, Snyder, RA, Nassif, EF, Krijgh, DD, Smith, JM, Tilney, G, Feng, C, Chiang, YJ, Torres, KE, Roubaud, MS, Scally, CP, Hunt, KK, Keung, EZ, Mericli, AF, Roland, CL. ASO Visual Abstract. Annals of surgical oncology 31(6):4150-4151, 2024. e-Pub 2024. PMID: 38546800.
- Nasr LF, Zoghbi M, Lazcano R, Nakazawa M, Bishop AJ, Farooqi A, Mitra D, Guadagnolo BA, Benjamin R, Patel S, Ravi V, Araujo DM, Livingston A, Zarzour MA, Conley AP, Ratan R, Somaiah N, Lazar AJ, Roland C, Keung EZ, Nassif Haddad EF. High-Grade Pleomorphic Sarcomas Treated with Immune Checkpoint Blockade: The MD Anderson Cancer Center Experience. Cancers (Basel) 16(9), 2024. e-Pub 2024. PMID: 38730715.
- Denu RA, Joseph CP, Urquiola ES, Byrd PS, Yang RK, Ratan R, Zarzour MA, Conley AP, Araujo DM, Ravi V, Nassif Haddad EF, Nakazawa MS, Patel S, Wang WL, Lazar AJ, Somaiah N. Utility of Clinical Next Generation Sequencing Tests in KIT/PDGFRA/SDH Wild-Type Gastrointestinal Stromal Tumors. Cancers (Basel) 16(9), 2024. e-Pub 2024. PMID: 38730662.
- Roland CL, Nassif Haddad EF, Keung EZ, Wang WL, Lazar AJ, Lin H, Chelvanambi M, Parra ER, Wani K, Guadagnolo BA, Bishop AJ, Burton EM, Hunt KK, Torres KE, Feig BW, Scally CP, Lewis VO, Bird JE, Ratan R, Araujo D, Zarzour MA, Patel S, Benjamin R, Conley AP, Livingston JA, Ravi V, Tawbi HA, Lin PP, Moon BS, Satcher RL, Mujtaba B, Witt RG, Traweek RS, Cope B, Lazcano R, Wu CC, Zhou X, Mohammad MM, Chu RA, Zhang J, Damania A, Sahasrabhojane P, Tate T, Callahan K, Nguyen S, Ingram D, Morey R, Crosby S, Mathew G, Duncan S, Lima CF, Blay JY, Fridman WH, Shaw K, Wistuba I, Futreal A, Ajami N, Wargo JA, Somaiah N. A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma. Nat Cancer 5(4):625-641, 2024. e-Pub 2024. PMID: 38351182.
- Thirasastr P, Sutton TL, Joseph CP, Lin H, Amini B, Mayo SC, Araujo D, Benjamin RS, Conley AP, Livingston JA, Ludwig J, Patel S, Ratan R, Ravi V, Zarzour MA, Nassif Haddad EF, Nakazawa MS, Zhou X, Heinrich MC, Somaiah N. Outcomes of Late-Line Systemic Treatment in GIST: Does Sequence Matter?. Cancers (Basel) 16(5), 2024. e-Pub 2024. PMID: 38473266.
- Nakazawa MS, Livingston JA, Zarzour MA, Bishop AJ, Ratan R, Ludwig JA, Araujo DM, Somaiah N, Ravi V, Nassif EF, Roland CL, Lazar AJ, Guadagnolo BA, Harrison DJ, Benjamin RS, Patel SR, Conley AP. Clinical characteristics and outcomes of adult alveolar rhabdomyosarcoma patients on first-line systemic therapies: A single-institution cohort. Rare Tumors 16:20363613241271669, 2024. e-Pub 2024. PMID: 39105190.
- Erstad DJ, Chiang YJ, Witt RG, Cope B, Nassif EF, Scally CP, Torres KE, Feig BW, Hunt KK, Bishop AJ, Guadagnolo BA, Roland CL, Keung EZ. ASO Visual Abstract: Clinical Impact of External Beam Radiotherapy for Surgically Resected Primary Retroperitoneal Liposarcoma. Ann Surg Oncol 30(2):941-942, 2023. e-Pub 2023. PMID: 36161369.
- Thirasastr P, Lin H, Amini B, Wang WL, Cloutier JM, Nassif EF, Keung EZ, Roland CL, Feig B, Araujo D, Benjamin RS, Conley AP, Livingston JA, Ludwig J, Patel S, Ratan R, Ravi V, Zarzour MA, Zhou X, Somaiah N. Retrospective evaluation of the role of gemcitabine-docetaxel in well-differentiated and dedifferentiated liposarcoma. Cancer Med 12(4):4282-4293, 2023. e-Pub 2023. PMID: 36151848.
- Erstad DJ, Chiang YJ, Witt RG, Cope B, Nassif EF, Scally CP, Torres KE, Feig BW, Hunt KK, Bishop AJ, Guadagnolo BA, Roland CL, Keung EZ. Clinical Impact of External Beam Radiotherapy for Surgically Resected Primary Retroperitoneal Liposarcoma. Ann Surg Oncol 30(2):926-940, 2023. e-Pub 2023. PMID: 36115928.
- Torregrosa C, Pernot S, Vaflard P, Perret A, Tournigand C, Randrian V, Doat S, Neuzillet C, Moulin V, Stouvenot M, Roth G, Darbas T, Auberger B, Godet T, Jaffrelot M, Lambert A, Dubreuil O, Gluszak C, Bernard-Tessier A, Turpin A, Palmieri LJ, Bouche O, Goujon G, Lecomte T, Sefrioui D, Locher C, Grados L, Gignoux P, Trager S, Nassif E, Saint A, Hammel P, Lecaille C, Bureau M, Perrier M, Botsen D, Bourgeois V, Taieb J, Auclin E. FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX-bevacizumab failure for COlorectal cancer (BEFLICO): An AGEO multicenter study. Int J Cancer 151(11):1978-1988, 2022. e-Pub 2022. PMID: 35833561.
- Lazcano R*, Barreto CM, Salazar R, Carapeto F, Traweek RS, Leung CH, Gite S, Mehta J, Ingram DR, Wani KM, Vu KT, Parra ER, Lu W, Zhou J, Witt RG, Cope B, Thirasastr P, Lin HY, Scally CP, Conley AP, Ratan R, Livingston JA, Zarzour AM, Ludwig J, Araujo D, Ravi V, Patel S, Benjamin R, Wargo J, Wistuba II, Somaiah N, Roland CL, Keung EZ, Solis L, Wang WL, Lazar AJ, Nassif EF. The immune landscape of undifferentiated pleomorphic sarcoma. Front Oncol 12:1008484, 2022. e-Pub 2022. PMID: 36313661.
- Witt RG, Cope B, Erstad DJ, Chiang YJ, Nassif EF, Scally CP, Torres KE, Hunt KK, Feig BW, Roland CL, Keung EZ. Sentinel Lymph Node Biopsy and Formal Lymphadenectomy for Soft Tissue Sarcoma: A Single Center Experience of 86 Consecutive Cases. Ann Surg Oncol 29(11):7092-7100, 2022. e-Pub 2022. PMID: 35501583.
- Somaiah N, Conley AP, Parra ER, Lin H, Amini B, Solis Soto L, Salazar R, Barreto C, Chen H, Gite S, Haymaker C, Nassif EF, Bernatchez C, Mitra A, Livingston JA, Ravi V, Araujo DM, Benjamin R, Patel S, Zarzour MA, Sabir S, Lazar AJ, Wang WL, Daw NC, Zhou X, Roland CL, Cooper ZA, Rodriguez-Canales J, Futreal A, Soria JC, Wistuba II, Hwu P. Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial. Lancet Oncol 23(9):1156-1166, 2022. e-Pub 2022. PMID: 35934010.
- Nassif EF, Cope B, Traweek R, Witt RG, Erstad DJ, Scally CP, Thirasastr P, Zarzour MA, Ludwig J, Benjamin R, Bishop AJ, Guadagnolo BA, Ingram D, Wani K, Wang WL, Lazar AJ, Torres KE, Hunt KK, Feig BW, Roland CL, Somaiah N, Keung EZ. Real-world use of palbociclib monotherapy in retroperitoneal liposarcomas at a large volume sarcoma center. Int J Cancer 150(12):2012-2024, 2022. e-Pub 2022. PMID: 35128664.
- Nassif EF, Blay JY, Massard C, Dufresne A, Brahmi M, Cassier P, Ray-Coquard I, Pautier P, Leary A, Sunyach MP, Bahleda R, Levy A, Le Pechoux C, Honoré C, Mir O, Le Cesne A. Early phase trials in soft-tissue sarcomas: clinical benefit of inclusion in early lines of treatment, molecular screening, and histology-driven trials. ESMO Open 7(2):100425, 2022. e-Pub 2022. PMID: 35255445.
- Nassif EF, Auclin E, Bahleda R, Honoré C, Mir O, Dumont S, Mery B, Hodroj K, Brahmi M, Trédan O, Ray-Coquard I, Blay JY, Massard C, Le Cesne A, Dufresne A. TP53 Mutation as a Prognostic and Predictive Marker in Sarcoma: Pooled Analysis of MOSCATO and ProfiLER Precision Medicine Trials. Cancers (Basel) 13(13), 2021. e-Pub 2021. PMID: 34282771.
- Nassif EF, Mlecnik B, Thibault C, Auvray M, Bruni D, Colau A, Compérat E, Bindea G, Catteau A, Fugon A, Boquet I, Martel M, Camparo P, Colin P, Zakopoulou R, Bamias A, Bennamoun M, Barthere X, D'acremont B, Lefevre M, Audenet F, Mejean A, Verkarre V, Oudard S, Galon J. The Immunoscore in Localized Urothelial Carcinoma Treated with Neoadjuvant Chemotherapy: Clinical Significance for Pathologic Responses and Overall Survival. Cancers (Basel) 13(3):1-14, 2021. e-Pub 2021. PMID: 33525361.
- Boilève A, Dufresne A, Chamseddine A, Nassif E, Dumont S, Brahmi M, Adam J, Rouleau E, Karanian M, Haddad V, Faron M, Honoré C, Meeus P, Le Cesne A, Blay JY, Mir O. Outcomes of patients with metastatic gastrointestinal stromal tumors (GIST) treated with multi-kinase inhibitors other than imatinib as first-line treatment. ESMO Open 5(6):e001082, 2020. e-Pub 2020. PMID: 33246932.
- Honoré C, Delhorme JB, Nassif E, Faron M, Ferron G, Bompas E, Glehen O, Italiano A, Bertucci F, Orbach D, Pocard M, Quenet F, Blay JY, Carrere S, Chevreau C, Mir O, Le Cesne A, Malignancies (RENAPE) FNFRP, Network (NETSARC) FSC. Can we cure patients with abdominal Desmoplastic Small Round Cell Tumor? Results of a retrospective multicentric study on 100 patients. Surg Oncol 29:107-112, 2019. e-Pub 2019. PMID: 31196472.
Other Articles
- Denu RA, Dann AM, Keung EZ, Nakazawa MS, Nassif Haddad EF The Future of Targeted Therapy for Leiomyosarcoma. Cancers (Basel) 16(5), 2024. PMID: 38473300.
- Nassif EF, Keung EZ, Thirasastr P, Somaiah N Myxoid Liposarcomas: Systemic Treatment Options. Curr Treat Options Oncol 24(4):274-291, 2023. PMID: 36853469.
- Cope BM, Traweek RS, Lazcano R, Keung EZ, Lazar AJ, Roland CL, Nassif EF Targeting the Molecular and Immunologic Features of Leiomyosarcoma. Cancers (Basel) 15(7), 2023. PMID: 37046760.
- Gingrich AA, Nassif EF, Roland CL, Keung EZ The Landscape of Immunotherapy for Retroperitoneal Sarcoma. Curr Oncol 30(2):2144-2158, 2023. PMID: 36826126.
- Nassif EF, Joseph CP, Lazcano R, Joseph JT, Thirasastr P, Lazar AJ, Somaiah N Case report: Responses to the combination of gemcitabine with sirolimus in two patients with TSC-mutated sarcomas. Front Oncol 13:1046442, 2023. PMID: 36845725.
- Traweek RS, Cope BM, Roland CL, Keung EZ, Nassif EF, Erstad DJ Targeting the MDM2-p53 pathway in dedifferentiated liposarcoma. Front Oncol 12:1006959, 2022. PMID: 36439412.
- Roulleaux Dugage M*, Nassif EF*, Italiano A, Bahleda R Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review. Front Immunol 12:775761, 2021. PMID: 34925348.
- Nassif EF, Maloney N, Conley AP, Keung EZ Disseminated Coccidioidomycosis Following COVID-19 Mimicking Metastatic Thoracic Relapse of Well-Differentiated Liposarcoma: A Case Report. Front Med (Lausanne) 8:715939, 2021. PMID: 34589500.
- Nassif EF, Thibault C, Oudard S, Galon J Precision immunity: Immunoscore and neoadjuvant treatment in bladder cancer. Oncoimmunology 10(1):1888488, 2021. PMID: 33659099.
- Nassif EF, Arsène-Henry A, Kirova YM Brain metastases and treatment: multiplying cognitive toxicities. Expert Rev Anticancer Ther 19(4):327-341, 2019. PMID: 30755047.
- Nassif E, Thibault C, Vano Y, Fournier L, Mauge L, Verkarre V, Timsit MO, Mejean A, Tartour E, Oudard S Sunitinib in kidney cancer: 10 years of experience and development. Expert Rev Anticancer Ther 17(2):129-142, 2017. PMID: 27967249.
Abstracts
- Denu RA, Zheng Z, Jiang Y, Kochat V, Arslan E, Truong DD, Padron W, Ratan R, Somaiah N, Roland CL, Soliman PT, Meyer LA, Lazar AJ, Nassif Haddad EF, Keung EZ, Rai K. Leiomyosarcoma is characterized by two distinct subtypes driven by NFI or AP1 transcription factors. AACR Annual Meeting, 2025. e-Pub 2025.
- Ravi N*, Nakazawa M, Livingston J, Ratan R, Zarzour MA, Conley AP, Araujo D, Ravi V, Somaiah N, Patel S, Nassif Haddad EF. Incidence of germline genetic mutations identified on standard-of-care genomic sequencing for advanced sarcomas. CTOS Annual Meeting, 2024. e-Pub 2024.
- Kochat V, Arslan E, Denu RA, Truong DD, Weistuch C, Divenko M, Wu M, Padron W, Ingram DR, Wani KM, Roland CL, Keung EZ, Nassif Haddad EF, Lazar AJ, Ludwig JA, Somaiah N, Rai K. Single Nuclear Multiome Profiling in Matched Well- and De-Differentiated Liposarcoma Identifies Potential Drivers of De-Differentiation and Underlying Epigenetic Programs. CTOS Annual Meeting, 2024. e-Pub 2024.
- Malik N, Chiang Y, Keung E, Nassif Haddad E, Peterson S, Nguyen S, Torres K, Hunt K, Bishop A, Guardado A, Somaiah N, Roland C, Scally C, Lyu H. Health-Related Quality of Life in Patients with Resectable Retroperitoneal Dedifferentiated Liposarcoma (DDLPS) Treated with Neoadjuvant Checkpoint Blockade in a Randomized Phase II Clinical Trial. CTOS Annual Meeting, 2024. e-Pub 2024.
- Arifin AJ, Bishop AJ, Mitra D, Araujo DM, Nassif Haddad EF, Ratan R, Livingston J, Lewis VO, Lin PP, Moon BS, Keung E, Roland CL, Scally C, Guadagnolo B, Farooqi AS. Addressing the Primary Site in Patients with Metastatic Soft Tissue Sarcoma: Is There a role for a Combined Modality Treatment?. CTOS Annual Meeting, 2024. e-Pub 2024.
- Denu RA*, Zheng Z, Kochat V, Arslan E, Nassif Haddad EF, Rai K, Keung EZ. Integrated Atlas of Single Cell Transcriptome and Chromatin Accessibility in Leiomyosarcoma. CTOS Annual Meeting, 2024. e-Pub 2024.
- Fields B, Ajami N, Chelvanambi M, Damania A, Daniel-MacDougall C, Keung E, Nassif Haddad EF, Traweek R, Wargo J, Witt R, Holder A, Roland C. High Social Vulnerability Is Associated with Decreased Richness and Variability in the Gut Microbiome and Decreased Survival in Melanoma and Sarcoma Patients Treated with Immune Checkpoint Blockade. SITC 39th Annual Meeting, 2024. e-Pub 2024.
- Arifin AJ, Bishop AJ, Mitra D, Araujo DM, Nassif Haddad EF, Ratan R, Livingston J, Lewis VO, Lin PP, Moon BS, Keung E, Roland CL, Scally C, Guadagnolo B, Farooqi AS. Outcomes following combined modality treatment to the primary site in patients with metastatic soft tissue sarcoma. ASTRO 2024 Annual Meeting, 2024. e-Pub 2024.
- Ryan Austin Denu, Rossana Lazcano Segura, Ahsan Saleem Farooqi, Davis Ingram, Khalida M. Wani, Yiming Cai, Keila E. Torres, Emily Zhi-Yun Keung, Christina Lynn Roland, Neeta Somaiah, Haoqiang Ying, Jason T. Huse, Kunal Rai, Anthony Paul Conley, Shreyaskumar Patel, Wei-Lien Wang, Alexander J. Lazar, Nassif Haddad EF, The University of Texas MD Anderson Cancer Center, Houston, TX, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, The University of Texas MD Anderson Cancer Center, New York, TX, Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX. Impact of ATRX loss on survival and immune microenvironment in multiple sarcoma subtypes. ASCO Annual Meeting, 2024. e-Pub 2024.
- Pujita Munnangi, Bridgette L. King, Y. Sabrina Chiang, Anthony Paul Conley, Dejka M. Araujo, J. Andrew Livingston, Joseph Aloysius Ludwig, Michael Nakazawa, Nassif Haddad EF, Vinod Ravi, Ravin Ratan, Maria Alejandra Zarzour, Shreyaskumar Patel, Keila E. Torres, Neeta Somaiah, Texas A&M School of Engineering Medicine, Houston, TX, The University of Texas MD Anderson Cancer Center, Houston TX, Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, The University of Texas MD Anderson Cancer Center Hematology/Oncology Fellowship, Houston, TX, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. Systemic therapy in NF-1 associated malignant peripheral nerve sheath tumors (MPNST). ASCO Annual Meeting, 2024. e-Pub 2024.
- Alicia Gingrich, Hannah Beird, Rossana Lazcano Segura, Ryan Denu, Michael Nakazawa, Ravin Ratan, J. Andrew Livingston, Maria Alejandra Zarzour, Anthony Paul Conley, Neeta Somaiah, Dejka M. Araujo, S. Shreyaskumar Patel, Christina Lynn Roland, Andrew Futreal, Alexander J. Lazar, Emily Zhi-Yun Keung, Nassif Haddad EF, Rare Tumor Initiative Team, Patient Mosaic Team; The University of Texas MD Anderson Cancer Center, Houston, TX, Department of Genomic Medicine; The University of Texas MD Anderson Cancer Center, Houston, TX. Immune infiltrate analysis to reveal distinct immune classes for leiomyosarcomas. ASCO Annual Meeting, 2024. e-Pub 2024.
- Nassif EF, Lu H, Stanford M, Millerchip K, Romero D, Matejka B, Malke J, Gershenwald J, Kumari S, Mak D, Lin A, Burke J, Wang W, Lazar A, Somaiah N, Haymaker C, Roland C, Keung E. Peripheral CD38+ Effector Memory T cells are Dynamic Biomarkers of Response to Neoadjuvant Immune Checkpoint Blockade in Patients with Resectable Dedifferentiated Liposarcomas and Undifferentiated Pleomorphic Sarcomas. AACR Annual Meeting, 2024. e-Pub 2024.
- Chelvanambi M, Melendez B, Nassif EF, Lazcano RN, Lastrapes MJ, Bhushan BS, Johnson SB, Wani K, Ingram DR, Seo Y, Helmink BA, White MG, Witt RG, Diggs LP, Morad G, Zelazowska M, Paul S, Dimitriou F, Damania AV, Wong MC, Somaiah N, Ajami NJ, Keung EZ, Fridman WH, Allison JP, Sharma P, McBride KM, Cascone T, Roland CL, Lazar AJ, Wargo JA. Spatial profiling reveals unique immune-transcriptomic features of tertiary lymphoid structures in melanoma. AACR Annual Meeting 84(6 Supplement), 2024. e-Pub 2024.
- Nassif EF, Beird H, Mitra A, Liu B, McBride K, Wang W, Ingram D, Wani K, Keung EZ, Initiative Team RT, Team PM, Zarzour A, Conley A, Araujo D, Livingston J, Ratan R, Patel S, Ravi V, Benjamin R, Lazar AJ, Roland CL, Futreal P, Somaiah N. Histology Specific Intratumoral B-Cell Biology in Alveolar Soft-Part Sarcomas (ASPS) in Response to Durvalumab-Tremelimumab (D-T). CTOS Annual Meeting, 2023. e-Pub 2023.
- Livingston J, Cloutier J, Conley AP, Gorlick R, Benjamin RS, Posey K, Nassif E, Zarzour M, Araujo D, Ratan R, Ravi V, Somaiah N, Lin H, Leung CH, Lazar AJ, Lewis VO, Lin P, Amini B, Valenzuela RF, Patel S, Wang W. Chemotherapy and Prognostic Significance of Extent of Dedifferentiation in Dedifferentiated Parosteal Osteosarcoma. CTOS Annual Meeting, 2023. e-Pub 2023.
- Torres MB*, Leung CH, Keung E, Feng C, Beird H, Zarzour A, Scally C, Hunt K, Conley A, Bishop A, Guadagnolo B, Farooqi A, Mitra D, Araujo D, Livingston A, Ratan R, Patel S, Ravi V, Lazar A, Roland CL, Somaiah N, Nassif EF. Dedifferentiated Liposarcomas Treated With Immune Checkpoint Blockade: The MD Anderson Experience. CTOS Annual Meeting, 2023. e-Pub 2023.
- Nassif Haddad EF, Lazcano R, Morey R, Ingram D, Wani K, Gingrich A, Nakazawa M, Denu R, Roland CL, Somaiah N, Livingston JA, Zarzour MA, Conley AP, Araujo D, Ludwig J, Patel S, Benjamin R, Ravi V, Ratan R, Keung EZ, Lazar A. Patterns of Expression of Immune Biomarkers in Leiomyosarcomas (LMS). NCI Strategic Advances in Sarcoma Science, 2023. e-Pub 2023.
- Thirasastr P, Lin HY, Nassif EF, Wang W, Araujo DM, Benjamin RS, Conley AP, Livingston J, Ludwig JA, Patel S, Ratan R, Ravi V, Zarzour MA, Zhou X, Somaiah N. Clinical implications of recurring mutations in myxoid liposarcoma (MLS). ASCO Annual Meeting, 2023. e-Pub 2023.
- Traweek RS, Lazcano R, Cope BM, Bishop AJ, Guadagnolo BA, Ingram DR, Wani K, Lazar AJ, Wang WL, Scally CP, Keung EZ, Torres KE, Hunt KK, Nassif EF, Roland CL. Major Pathologic Response (MPR) Following Neoadjuvant Radiation Therapy (RT) +/- immune-checkpoint Blockade (ICB) Is Associated with Improved Survival in Undifferentiated Pleomorphic Sarcoma (UPS). American Radium Society Annual Meeting, 2023. e-Pub 2023.
- Traweek RS, Witt RG, Snyder RA, Nassif E, Lyu H, Krijgh DD, Smith JM, Tilney GS, Fen C, Torres KE, Roubaud ME, Scally CP, Hunt KK, Feig BW, Keung EZ, Mericli AF, Roland CL. Social vulnerability is associated with worse survival among patients with extremity and truncal soft-tissue sarcoma. Society of Surgical Oncology Annual Meeting, 2023. e-Pub 2023.
- Nassif EF, Liu B, Wang WL, Lazar AJ, Ingram D, Wani K, Duncan S, Tate T, Mathew G, Crosby S, Shaw K, Zelazowska M, Feig BW, Torres KE, Hunt KK, Guadagnolo BA, Bishop AJ, Futreal A, Wargo JA, Somaiah N, McBride K, Roland CL, Keung EZ. B-Cell Receptor (BCR) Repertoire is a Dynamic Biomarker of Survival in Sarcoma Patients Treated with Neoadjuvant Immune Checkpoint Blockade (ICB). SITC Annual Meeting, 2022. e-Pub 2022.
- Genestie C, Giudici F, Leary A, Scoazec JY, Nassif E, Pautier P. Immune Infiltration As Prognostic Factors in Metastatic Leiomyosarcoma. CTOS Annual Meeting, 2022. e-Pub 2022.
- Traweek RS, Witt RG, Nassif EF, Ajami NJ, Mishra AK, Damania AV, Chelvanambi M, Wang WL, Lazar AJ, Keung EZ, Torres KE, Scally CP, Zhang X, Daniel-MacDougall CR, Wargo JA, Somaiah N, Roland CL. Dietary fiber intake is associated with increased tertiary lymphoid structures in dedifferentiated liposarcoma following immune checkpoint blockade. SITC Annual Meeting, 2022. e-Pub 2022.
- Chelvanambi M, Deboever N, Nassif EF, Damania AV, Chen L, Leung CH, Wu CC, Keung EZ, Witt RG, White MG, Johnson SB, Wong MC, Mishra AK, Lastrapes MJ, Somaiah N, Kadara H, Basu S, Allison JP, Sharma P, McBride KM, Fridman WH, Heymach J, Sepesi B, Ajami NJ, Roland CL, Wargo JA, Cascone T. Metagenomic sequencing reveals unique gut microbial features associated with tertiary lymphoid structures in response to immune checkpoint blockade in solid cancers. SITC Annual Meeting, 2022. e-Pub 2022.
- Nassif EF, Keung EZ, Jiang P, Reuben A, Crosby S, Mathew G, Lazar AJ, Torres KE, Wang WL, Guadagnolo BA, Bishop AJ, Hunt KK, Bird JE, Lewis VO, Conley AP, Wargo JA, Somaiah N, Roland CL. Peripheral Immune Biomarkers of Survival in Patients with Resectable Dedifferentiated Liposarcomas (DDLPS) and Undifferentiated Pleomorphic Sarcomas (UPS) Treated with Neoadjuvant Nivolumab +/- Ipilimumab (neoICB). ESMO Annual Meeting, 2022. e-Pub 2022.
- Keung EZ, Nassif EF, Lin HY, Lazar AJ, Torres KE, Wang WL, Guadagnolo AB, Bishop AJ, Hunt KK, Feig BW, Bird JE, Lewis VO, Ratan R, Patel S, McBride K, Liu B, Zelazowska M, Wargo JA, Roland CL, Somaiah N. Randomized phase II study of neoadjuvant immune checkpoint blockade (ICB) for surgically resectable undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS): survival results after 2 years of follow-up and intratumoral B-Cell Receptor (BCR) correlates. ASCO Annual Meeting, 2022. e-Pub 2022.
- Nassif EF, Chelvanambi M, Chen L, Wu CC, Damania A, Keung EZ, Witt R, White MG, Ajami NJ, Wong MC, Somaiah N, Sepesi B, Basu S, Allison JP, Sharma P, McBride K, Fridman WH, Wargo JA, Cascone T, Roland CL. Identifying gut microbial signatures associated with B-cells and tertiary lymphoid structures (TLS) in the tumor microenvironment (TME) in response to immune checkpoint blockade (ICB). ASCO Annual Meeting, 2022. e-Pub 2022.
- Nassif EF, Wu CC, Akdemir K, Witt RG, Traweek R, Cope B, Thirasastr P, Tate T, Mathew G, Crosby S, Chu R, Mohammad M, Shaw K, Ingram D, Wani K, Lazar AJ, Wang WL, Duncan S, Guadagnolo BA, Bishop AJ, Lewis V, Bird JE, Torres KE, Hunt KK, Feig BW, Scally CP, Ratan R, Patel S, Benjamin R, Satcher R, McBride K, Fridman WH, Wistuba I, Futreal A, Wargo JA, Somaiah N, Roland CL, Keung EZ. Antigen presentation and processing pathway is associated with early relapse after neoadjuvant immune checkpoint blockade (ICB) in dedifferentiated liposarcomas (DDLPS). AACR special conference on sarcoma, 2022. e-Pub 2022.
- Traweek R*, Keung EZ, Ajami NJ, Duncan S, Burton E, Tate T, Callahan K, Ingram D, Wani K, Lazar AJ, Wang WL, Guadagnolo BA, Bishop AJ, Wargo JA, Somaiah N, Roland CL, Nassif EF. Fecal microbiome in soft-tissue sarcoma (STS) patients treated with neoadjuvant immune checkpoint blockade (ICB). ESMO Immuno-Oncology Annual Meeting, 2021. e-Pub 2021.
- Nassif EF, Le Cesne A, Massard C, Mezquita L, Roulleaux-Dugage M, Bahleda R, Dufresne A, Brahmi M, Ray-Coquard I, Pautier P, Leary A, Levy A, Le Pechoux C, Honore C, Mir O, Besse B, Blay JY, Auclin E. Association of Lung Immune Prognostic Index (LIPI) with Progression-free survival (PFS) in soft-tissue sarcoma (STS) patients treated with immunotherapy (IO) in early phase trials. ESMO Immuno-Oncology Annual Meeting, 2021. e-Pub 2021.
- Keung EZ, Nassif EF, Lin H, Lazar AJ, Wang WL, Parra ER, Lima CF, Wistuba I, Guadagnolo BA, Bishop AJ, Lewis V, Torres KE, Hunt KK, Feig BW, Scally CP, Al Rawi AN, Crosby S, Mathew G, Ingram D, Wani K, Wargo JA, Somaiah N, Roland CL. Immune infiltrates are associated with clinical outcomes in patients with resectable soft tissue sarcoma treated with neoadjuvant immune checkpoint blockade. SITC Annual Meeting, 2021. e-Pub 2021.
- Thirasastr P, Amini B, Lin H, Roland C, Keung EZ, Nassif E, Araujo D, Benjamin RS, Conley AP, Gorlick R, Livingston JA, Ludwig J, Patel S, Ratan R, Ravi V, Zarzour A, Zhou X, Somaiah N. Efficacy of gemcitabine-docetaxel in dedifferentiated liposarcoma. CTOS Annual Meeting, 2021. e-Pub 2021.
- Nassif EF, Roland CL, Thirasastr P, Scally CP, Zarzour A, Valenzuela R, Torres KE, Hunt KK, Feig BW, Wang WL, Lazar AJ, Somaiah N, Keung EZ. Surgical outcomes of patients with well-differentiated and dedifferentiated retroperitoneal liposarcomas treated with palbociclib. CTOS Annual Meeting, 2021. e-Pub 2021.
- Nassif EF, Auclin E, Bahleda R, Honoré C, Mir O, Dumont S, Mery B, Hodroj K, Brahmi M, Trédan O, Ray-Coquard I, Blay JY, Massard C, Le Cesne A, Dufresne A, Le Pechoux C, Levy A, Komaki R. Impact of peri-operative radiotherapy on localized sarcomas with TP53 alterations: retrospective pooled analysis of two precision medicine trials. American Radium Society Annual Meeting, 2021. e-Pub 2021.
- Nassif EF, Bahleda R, Auclin E, Honoré C, Dumont S, Brahmi M, Tredan O, Mir O, Ray-Coquard I, Le Cesne A, Blay JY, Massard C, Dufresne A. TP53 as a prognostic marker in patients with advanced sarcoma: a pooled analysis of MOSCATO and ProilER studies. CTOS Annual Meeting, 2020. e-Pub 2020.
- Nassif EF, Mlecnik B, Thibault C, Barthere X, Auvray M, Bruni D, Comperat E, Colau A, Hermitte F, Camparo P, Colin P, Bruno D, Bennamoun M, Audenet F, Mejean A, Verkarre V, Zakopoulou R, Bamias A, Oudard S, Galon J. The Immunoscore in patients with urothelial carcinoma treated with neoadjuvant chemotherapy: clinical significance for pathological response and survival. ESMO Annual Meeting, 2019. e-Pub 2019.
- Delhorme JB, Nassif E, Ferron G, Bompas E, Adam J, Glehen O, Italiano A, Bertucci F, Orbach D, Le Cesne A, Blay JY, Chevreau CM, Mir O, Honoré C. Can we cure patients with abdominal desmoplastic small round cell tumor? Results of a retrospective multicentric study on 100 patients. ESMO Annual Meeting, 2018. e-Pub 2018.
- Assi TS, Le Cesne A, Nassif E, Cavalcanti A, Faron M, Ibrahim T, Le Pechoux C, Mir O, Adam J, Dumont S, Terrier P, Honore C. Adriamycin and ifosfamide-based regimen as induction chemotherapy in desmoplastic small round cell tumors: Results of a retrospective single-center study on 34 patients. ESMO Annual Meeting, 2018. e-Pub 2018.
- Nassif E, De Forceville L, Geraud A, Gantzer J, Honoré C, Dumont SN, Mir O, De Baere T, Blay JY, Le Cesne A. Retrospective study of complete remission imatinib-free metastatic gastro-intestinal stromal tumors (GIST). ASCO Annual Meeting, 2018. e-Pub 2018.
Book Chapters
- Nassif E, MD, L Roland AC, MD, MS, FACS. Impactful Perioperative Clinical Trials Advance Sarcoma Care. In: ASCO Daily News, 2022.
- Nassif E, MD, Somaiah AN, MD. Improving the Benchmark: Examining ASCO22 Histology-Specific Trials in Sarcoma. In: ASCO Daily News, 2022.
Letters to the Editor
- Nassif EF, Roland CL, Keung EZ. Reflections on the value of multidisciplinary oncology training by a medical oncologist. Eur J Surg Oncol 49: 1046-1047, 2023.
Selected Presentations & Talks
Local Presentations
- 2024. Biomedical Research As a Career: An International Scientist’s Perspective. Invited. ITERT Stem Education and Training Program Career Symposium - Career Paths in Biomedical Sciences: Charting your own adventure. Houston, Texas, US.
National Presentations
- 2025. SARC Talk Podcast. Invited. SARC, US.
- 2025. Update on Precision Oncology in Sarcoma. Invited. Vumedi, US.
- 2024. Personalized Medicine and Targeted Therapies in Sarcoma. Invited. Sarcoma Exchange, US.
- 2024. Identifying Biomarker-Based Immune Targets in Molecular Subtypes of Leiomyosarcomas. Invited. Inter-SPORE Sarcoma Center and LMS SPORE joint Translational Science Seminar Series, US.
International Presentations
- 2024. Integrated Atlas of Single Cell Transcriptome and Chromatin Accessibility in Leiomyosarcoma. Conference. CTOS. San Diego, US.
- 2024. Incidence of germline genetic mutations identified on standard-of-care genomic sequencing for advanced sarcomas. Conference. CTOS. San Diego, US.
- 2024. High Social Vulnerability Is Associated with Decreased Richness and Variability in the Gut Microbiome and Decreased Survival in Melanoma and Sarcoma Patients Treated with Immune Checkpoint Blockade. Poster. SITC. Houston, US.
- 2024. Addressing the Primary Site in Patients with Metastatic Soft Tissue Sarcoma: Is There a role for a Combined Modality Treatment?. Conference. CTOS. San Diego, US.
- 2024. Single Nuclear Multiome Profiling in Matched Well- and De-Differentiated Liposarcoma Identifies Potential Drivers of De-Differentiation and Underlying Epigenetic Programs. Conference. CTOS. San Diego, US.
- 2024. Health-Related Quality of Life in Patients with Resectable Retroperitoneal Dedifferentiated Liposarcoma (DDLPS) Treated with Neoadjuvant Checkpoint Blockade in a Randomized Phase II Clinical Trial. Poster. CTOS. San Diego, US.
- 2024. Chemotherapy and Immunotherapy in the Localized and Advanced Setting. Invited. CTOS Webinar “Sarcoma of the Year 2024”: Dedifferentiated Liposarcoma, US.
- 2024. Systemic therapy in NF-1 associated malignant peripheral nerve sheath tumors (MPNST). Conference. ASCO. Chicago, US.
- 2024. Immune infiltrate analysis to reveal distinct immune classes for leiomyosarcomas. Conference. ASCO. Chicago, US.
- 2024. Impact of ATRX loss on survival and immune microenvironment in multiple sarcoma subtypes. Conference. ASCO. Chicago, US.
- 2023. Clinical implications of recurring mutations in myxoid liposarcoma (MLS). Conference. ASCO. Chicago, US.
- 2023. Major Pathologic Response (MPR) Following Neoadjuvant Radiation Therapy (RT) +/- immune-checkpoint Blockade (ICB) Is Associated with Improved Survival in Undifferentiated Pleomorphic Sarcoma (UPS). Conference. Major Pathologic Response (MPR) Following Neoadjuvant Radiation Therapy (RT) +/- immune-checkpoint Blockade (ICB) Is Associated with Improved Survival in Undifferentiated Pleomorphic Sarcoma (UPS), US.
- 2023. Social vulnerability is associated with worse survival among patients with extremity and truncal soft-tissue sarcoma. Conference. Social vulnerability is associated with worse survival among patients with extremity and truncal soft-tissue sarcoma, US.
- 2022. B-Cell Receptor (BCR) Repertoire is a Dynamic Biomarker of Survival in Sarcoma Patients Treated with Neoadjuvant Immune Checkpoint Blockade (ICB). Conference. SITC, US.
- 2022. Dietary fiber intake is associated with increased tertiary lymphoid structures in dedifferentiated liposarcoma following immune checkpoint blockade. Conference. SITC, US.
- 2022. Metagenomic sequencing reveals unique gut microbial features associated with tertiary lymphoid structures in response to immune checkpoint blockade in solid cancers. Conference. SITC, US.
- 2022. Peripheral Immune Biomarkers of Survival in Patients with Resectable Dedifferentiated Liposarcomas (DDLPS) and Undifferentiated Pleomorphic Sarcomas (UPS) Treated with Neoadjuvant Nivolumab +/- Ipilimumab (neoICB). Conference. ESMO, FR.
- 2022. Randomized phase II study of neoadjuvant immune checkpoint blockade (ICB) for surgically resectable undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS): survival results after 2 years of follow-up and intratumoral B-Cell Receptor (BCR) correlates. Conference. ASCO, US.
- 2022. Identifying gut microbial signatures associated with B-cells and tertiary lymphoid structures (TLS) in the tumor microenvironment (TME) in response to immune checkpoint blockade (ICB). Conference. ASCO, US.
- 2022. Antigen presentation and processing pathway is associated with early relapse after neoadjuvant immune checkpoint blockade (ICB) in dedifferentiated liposarcomas (DDLPS). Conference. AACR, CA.
- 2021. Fecal microbiome in soft-tissue sarcoma (STS) patients treated with neoadjuvant immune checkpoint blockade (ICB). Conference. ESMO, CH.
- 2021. Association of Lung Immune Prognostic Index (LIPI) with Progression-free survival (PFS) in soft-tissue sarcoma (STS) patients treated with immunotherapy (IO) in early phase trials. Conference. ESMO, CH.
- 2021. Efficacy of gemcitabine-docetaxel in dedifferentiated liposarcoma. Conference. CTOS, US.
- 2021. Immune infiltrates are associated with clinical outcomes in patients with resectable soft tissue sarcoma treated with neoadjuvant immune checkpoint blockade. Conference. SITC, US.
- 2021. Surgical outcomes of patients with well-differentiated and dedifferentiated retroperitoneal liposarcomas treated with palbociclib. Conference. CTOS, US.
- 2021. Impact of peri-operative radiotherapy on localized sarcomas with TP53 alterations: retrospective pooled analysis of two precision medicine trials. Conference. Impact of peri-operative radiotherapy on localized sarcomas with TP53 alterations: retrospective pooled analysis of two precision medicine trials, US.
- 2020. TP53 as a prognostic marker in patients with advanced sarcoma: a pooled analysis of MOSCATO and ProilER studies. Conference. CTOS, US.
- 2019. The Immunoscore in patients with urothelial carcinoma treated with neoadjuvant chemotherapy: clinical significance for pathological response and survival. Conference. ESMO, ES.
- 2018. Adriamycin and ifosfamide-based regimen as induction chemotherapy in desmoplastic small round cell tumors: Results of a retrospective single-center study on 34 patients. Conference. ESMO, DE.
- 2018. Can we cure patients with abdominal desmoplastic small round cell tumor? Results of a retrospective multicentric study on 100 patient. Conference. ESMO, DE.
- 2018. Retrospective study of complete remission imatinib-free metastatic gastro-intestinal stromal tumors (GIST). Conference. ASCO, US.
Formal Peers
- 2023. Identifying Biomarker-Based Immune Strategies for Leiomyosarcoma. Invited. Identifying Biomarker-Based Immune Strategies fro Leiomyosarcoma. Boston, US.
Grant & Contract Support
| Date: | 2025 - 2030 |
| Title: | Overcoming T Cell Exclusion for Sarcoma: Molecular Mechanisms and Therapeutic Strategies |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | NIH R01 PAR25-301 |
| Date: | 2025 - 2027 |
| Title: | Investigating Rationale Combinations of Gemcitabine With Targeted Agents in Molecular Subgroups of Leiomyosarcomas |
| Funding Source: | Andrew Sabin Family Foundation Fellowship Award |
| Role: | PI |
| ID: | Andrew Sabin Family Foundation Fellowship Award |
| Date: | 2025 - 2027 |
| Title: | Spatial Interactions in the Microenvironment of Uterine Leiomyosarcomas |
| Funding Source: | American Association for Cancer Research |
| Role: | PI |
| ID: | American Association for Cancer Research |
| Date: | 2025 - 2027 |
| Title: | Comprehensive analysis of the LMS microenvironment using spatial profiling and mouse models |
| Funding Source: | LMS SPORE Developmental Research Project |
| Role: | PI |
| ID: | Comprehensive analysis of the LMS microenvironment using spatial profiling and mouse models |
| Date: | 2025 - 2030 |
| Title: | Rationale targeting of the cell cycle to sensitize soft tissue sarcomas to chemotherapy through a biomarker-based approach |
| Funding Source: | NATIONAL INSTITUTES OF HEALTH |
| Role: | PI |
| ID: | FP00023923 |
| Date: | 2025 - 2030 |
| Title: | Endogenous Circular RNAs limit abemaciclib anti-tumor immune responses |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01CA295834 |
| Date: | 2024 - 2026 |
| Title: | Phase I/II Study to Evaluate the Feasibility and Efficacy of Sequential Abemaciclib and Gemcitabine Treatment in Patients with Advanced Retinoblastoma (Rb) + Dedifferentiated Liposarcomas and Leiomyosarcomas |
| Funding Source: | AACR - Robert A Winn |
| Role: | PI |
| ID: | FP00022793_Winn CDA 2024 |
| Date: | 2024 - 2026 |
| Title: | Phase 1 gemcitabine and nab-sirolimus trial in patients with advanced LMS or sarcomas with loss-of-function TSC1 and TSC2 mutations |
| Funding Source: | Early Career Clinical and Translaonal Research Group (EC-CTRG) |
| Role: | PI |
| ID: | Early Career Clinical and Translaonal Research Group (EC-CTRG) |
| Date: | 2024 - 2027 |
| Title: | RA230272: Leveraging Tumor-associated B-cells and B cell receptors for therapeutic targeting strategies for patients with soft tissue sarcoma |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-I |
| ID: | HT9425-23-RCRP-IDA |
| Date: | 2024 - 2026 |
| Title: | Spatial Interactions In the Microenvironement of Uterine Leiomyosarcomas |
| Funding Source: | American Association for Cancer Research (AACR) |
| Role: | PI |
| ID: | FP00022851 |
| Date: | 2024 - 2031 |
| Title: | 2023-0900 - A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas with TSC2 or TSC1 loss-of-function mutations or deletions |
| Funding Source: | Aadi |
| Role: | PI |
| ID: | RCTS # 00062997-MT; Award: AWD00008606_Investigator-Initiated Trial |
| Date: | 2024 - 2026 |
| Title: | 2023-1011 Observational Study of Biomarkers of Disease-related Outcomes in Patients with Metastatic Leiomyosarcoma Receiving Chemotherapy |
| Funding Source: | UNIVERSITY OF MICHIGAN |
| Role: | PI |
| ID: | FP00023495 |
| Date: | 2024 - 2026 |
| Title: | Phase II Randomized Trial of Adriamycin and Trabectedin followed by Trabectedin With or Without Olaparib Maintenance for Advanced or Metastatic Uterine Leiomyosarcoma |
| Funding Source: | NCI/NIH |
| Role: | PI |
| ID: | FP00023901_K12 Paul Calabresi_NCI |
| Date: | 2024 - 2027 |
| Title: | Cell Cycle Biomarkers of Sequential Abemaciclib and Gemcitabine Treatment for Advanced Rb1-positive Soft-Tissue Sarcomas |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-PI |
| ID: | FP00020990 |
| Date: | 2024 - 2026 |
| Title: | Cell Cycle Biomarkers of Sequential Abemaciclib and Gemcitabine Treatment for Advanced Rb1-positive Soft-Tissue Sarcomas |
| Funding Source: | National Leimyosarcoma Foundation |
| Role: | PI |
| ID: | FP00020252 |
| Date: | 2023 - 2025 |
| Title: | Immune Signatures in UPS: Prognostic, predictive and therapeutic relevance |
| Funding Source: | Sarcoma Foundation of America |
| Role: | Principal Investigator-MDACC |
| ID: | FP00018603 |
| Date: | 2023 - 2026 |
| Title: | Delineating strategies to enhance immunotherapy response via microbial targeting of tertiary lymphoid structures/B-cells |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | R-231 Individual Investigator Research Award |
| Date: | 2022 - 2024 |
| Title: | Identifying Biomarker-Based Immune Targets in Molecular Subtypes of Leiomyosarcomas |
| Funding Source: | Leiomyosarcoma SPORE |
| Role: | PI |
| ID: | FP00017710_Leiomyosarcoma SPORE Career Enhancement Program |
| Date: | 2022 - 2024 |
| Title: | Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas with B-Cell Receptors |
| Funding Source: | QuadW Foundation |
| Role: | PI |
| ID: | QuadW Foundation Fellowship |
| Date: | 2020 - 2020 |
| Title: | Impact of Immunotherapy on the Tumor Microenvironment, the Tumor Cells, and the Host in Soft-Tissue Sarcomas |
| Funding Source: | Fondation pour la Recherche Medicale |
| Role: | PI |
| ID: | Espoirs de la Recherche |
| Date: | 2018 - 2019 |
| Title: | Phenotypic Characterisation of CD4 TH1 Tumor-Infiltrating Lymphocytes in Renal Cell Carcinoma and Non-Small Cell Lung Cancer |
| Funding Source: | French National Cancer Institute |
| Role: | PI |
| ID: | Master of Science Funding |
| Date: | 2018 - 2019 |
| Title: | The Immunoscore in Localized Urothelial Carcinoma Treated with Neoadjuvant Chemotherapy |
| Funding Source: | FONCER |
| Role: | PI |
| ID: | FONCER |
Patient Reviews
CV information above last modified March 25, 2025